Boston Scientific fell 1.02% to $91.75, underperforming the S&P and down 10.98% over the last month versus a 3.7% gain for the Medical sector. Analysts expect the upcoming quarter to show EPS of $0.78 (+11.4% y/y) and revenue of $5.27bn (+15.5%), with full-year consensus at $3.04 and $20.06bn (+21.1% and +19.8%, respectively). The stock carries a Zacks Rank of #2 (Buy) but trades at a premium (forward P/E 30.5 vs. industry 19.4) and a PEG of 1.87 while the Medical‑Products industry ranks in the bottom third by Zacks—investors should watch the earnings release and any estimate revisions for signals on near-term share momentum.
Boston Scientific shares fell 1.02% to $91.75 in the latest session and have declined 10.98% over the past month versus a 3.7% gain for the Medical sector and a 0.89% rise in the S&P 500, signaling clear short-term underperformance ahead of an important earnings release. Analysts expect the upcoming quarter to deliver $0.78 in EPS (up 11.43% year-over-year) and $5.27 billion in revenue (up 15.46% y/y), while full-year consensus stands at $3.04 EPS (+21.12%) and $20.06 billion revenue (+19.77%), with the 30-day consensus EPS estimate unchanged. Boston Scientific carries a Zacks Rank of #2 (Buy), and the note emphasizes that analyst estimate revisions tend to drive near-term share momentum, so any change around the print would be a material market signal. Valuation and industry context are mixed: BSX trades at a forward P/E of 30.54 versus an industry 19.41 (a premium), has a PEG of 1.87 vs industry 1.95, and the Medical - Products industry ranks 165/250 (bottom ~34%), implying upside will likely require an earnings beat and positive estimate revisions while a miss could amplify downside given the stretched multiple.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.05
Ticker Sentiment
